These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
754 related articles for article (PubMed ID: 17405792)
1. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792 [TBL] [Abstract][Full Text] [Related]
2. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lee YH; Woo JH; Choi SJ; Ji JD; Song GG Lupus; 2010 May; 19(6):703-10. PubMed ID: 20064907 [TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Feng L; Deng J; Huo DM; Wu QY; Liao YH Nephrology (Carlton); 2013 Feb; 18(2):104-10. PubMed ID: 23113811 [TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Mak A; Cheak AA; Tan JY; Su HC; Ho RC; Lau CS Rheumatology (Oxford); 2009 Aug; 48(8):944-52. PubMed ID: 19494179 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials. Lee YH; Song GG Z Rheumatol; 2017 Dec; 76(10):904-912. PubMed ID: 27638015 [TBL] [Abstract][Full Text] [Related]
7. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials. Lee YH; Song GG Lupus; 2015 Dec; 24(14):1520-8. PubMed ID: 26162684 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Kamanamool N; McEvoy M; Attia J; Ingsathit A; Ngamjanyaporn P; Thakkinstian A Medicine (Baltimore); 2010 Jul; 89(4):227-235. PubMed ID: 20616662 [TBL] [Abstract][Full Text] [Related]
9. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Henderson LK; Masson P; Craig JC; Roberts MA; Flanc RS; Strippoli GF; Webster AC Am J Kidney Dis; 2013 Jan; 61(1):74-87. PubMed ID: 23182601 [TBL] [Abstract][Full Text] [Related]
10. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028 [TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. Touma Z; Gladman DD; Urowitz MB; Beyene J; Uleryk EM; Shah PS J Rheumatol; 2011 Jan; 38(1):69-78. PubMed ID: 20952473 [TBL] [Abstract][Full Text] [Related]
13. Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? Hogan J; Schwenk MH; Radhakrishnan J Kidney Int; 2012 Dec; 82(12):1256-60. PubMed ID: 22648298 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Liu LL; Jiang Y; Wang LN; Yao L; Li ZL Drugs; 2012 Jul; 72(11):1521-33. PubMed ID: 22818016 [TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy for lupus nephritis with mycophenolate mofetil or azathioprine. A meta-analysis . Deng J; Xie H; Zhu L; Luo L; Xie H Clin Nephrol; 2019 Mar; 91(3):172-179. PubMed ID: 30686286 [TBL] [Abstract][Full Text] [Related]
16. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis. Mok CC Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327 [TBL] [Abstract][Full Text] [Related]
17. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Contreras G; Tozman E; Nahar N; Metz D Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929 [TBL] [Abstract][Full Text] [Related]
18. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125 [TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis. Jiang YP; Zhao XX; Chen RR; Xu ZH; Wen CP; Yu J Medicine (Baltimore); 2020 Sep; 99(38):e22328. PubMed ID: 32957400 [TBL] [Abstract][Full Text] [Related]
20. Lupus nephritis: maintenance therapy for lupus nephritis--do we now have a plan? Lenz O; Waheed AA; Baig A; Pop A; Contreras G Clin J Am Soc Nephrol; 2013 Jan; 8(1):162-71. PubMed ID: 22917704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]